tetano
Editor, Senior Moderator
Sci Rep
. 2022 Sep 15;12(1):15517.
doi: 10.1038/s41598-022-19780-7.
Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies
Xia Cao[SUP] 1 [/SUP], Junki Maruyama[SUP] 2 [/SUP], Heyue Zhou[SUP] 1 [/SUP], Yanwen Fu[SUP] 1 [/SUP], Lisa Kerwin[SUP] 1 [/SUP], Colin Powers[SUP] 1 [/SUP], Rachel A Sattler[SUP] 2 [/SUP], John T Manning[SUP] 2 [/SUP], Alok Singh[SUP] 1 [/SUP], Reyna Lim[SUP] 1 [/SUP], Laura D Healy[SUP] 1 [/SUP], Sachi Johnson[SUP] 1 [/SUP], Elizabeth Paz Cabral[SUP] 1 [/SUP], Donghui Li[SUP] 1 [/SUP], Lucy Lu[SUP] 1 [/SUP], Arthur Ledesma[SUP] 1 [/SUP], Daniel Lee[SUP] 1 [/SUP], Susan Richards[SUP] 1 [/SUP], Laura Rivero-Nava[SUP] 1 [/SUP], Yan Li[SUP] 1 [/SUP], Weiqun Shen[SUP] 1 [/SUP], Karen Stegman[SUP] 1 [/SUP], Benjamin Blair[SUP] 1 [/SUP], Shinji Urata[SUP] 2 [/SUP], Magumi Kishimoto-Urata[SUP] 2 [/SUP], Jamie Ko[SUP] 1 [/SUP], Na Du[SUP] 1 [/SUP], Kyndal Morais[SUP] 1 [/SUP], Kate Lawrence[SUP] 1 [/SUP], Ianne Rivera[SUP] 1 [/SUP], Chin-I Pai[SUP] 1 [/SUP], Damien Bresson[SUP] 1 [/SUP], Mark Brunswick[SUP] 1 [/SUP], Yanliang Zhang[SUP] 1 [/SUP], Henry Ji[SUP] 3 [/SUP], Slobodan Paessler[SUP] 4 [/SUP], Robert D Allen[SUP] 1 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) continues to significantly impact the global population, thus countermeasure platforms that enable rapid development of therapeutics against variants of SARS-CoV-2 are essential. We report use of a phage display human antibody library approach to rapidly identify neutralizing antibodies (nAbs) against SARS-CoV-2. We demonstrate the binding and neutralization capability of two nAbs, STI-2020 and STI-5041, against the SARS-CoV-2 WA-1 strain as well as the Alpha and Beta variants. STI-2020 and STI-5041 were protective when administered intravenously or intranasally in the golden (Syrian) hamster model of COVID-19 challenged with the WA-1 strain or Beta variant. The ability to administer nAbs intravenously and intranasally may have important therapeutic implications and Phase 1 healthy subjects clinical trials are ongoing.
. 2022 Sep 15;12(1):15517.
doi: 10.1038/s41598-022-19780-7.
Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies
Xia Cao[SUP] 1 [/SUP], Junki Maruyama[SUP] 2 [/SUP], Heyue Zhou[SUP] 1 [/SUP], Yanwen Fu[SUP] 1 [/SUP], Lisa Kerwin[SUP] 1 [/SUP], Colin Powers[SUP] 1 [/SUP], Rachel A Sattler[SUP] 2 [/SUP], John T Manning[SUP] 2 [/SUP], Alok Singh[SUP] 1 [/SUP], Reyna Lim[SUP] 1 [/SUP], Laura D Healy[SUP] 1 [/SUP], Sachi Johnson[SUP] 1 [/SUP], Elizabeth Paz Cabral[SUP] 1 [/SUP], Donghui Li[SUP] 1 [/SUP], Lucy Lu[SUP] 1 [/SUP], Arthur Ledesma[SUP] 1 [/SUP], Daniel Lee[SUP] 1 [/SUP], Susan Richards[SUP] 1 [/SUP], Laura Rivero-Nava[SUP] 1 [/SUP], Yan Li[SUP] 1 [/SUP], Weiqun Shen[SUP] 1 [/SUP], Karen Stegman[SUP] 1 [/SUP], Benjamin Blair[SUP] 1 [/SUP], Shinji Urata[SUP] 2 [/SUP], Magumi Kishimoto-Urata[SUP] 2 [/SUP], Jamie Ko[SUP] 1 [/SUP], Na Du[SUP] 1 [/SUP], Kyndal Morais[SUP] 1 [/SUP], Kate Lawrence[SUP] 1 [/SUP], Ianne Rivera[SUP] 1 [/SUP], Chin-I Pai[SUP] 1 [/SUP], Damien Bresson[SUP] 1 [/SUP], Mark Brunswick[SUP] 1 [/SUP], Yanliang Zhang[SUP] 1 [/SUP], Henry Ji[SUP] 3 [/SUP], Slobodan Paessler[SUP] 4 [/SUP], Robert D Allen[SUP] 1 [/SUP]
Affiliations
- PMID: 36109550
- DOI: 10.1038/s41598-022-19780-7
Abstract
Coronavirus disease 2019 (COVID-19) continues to significantly impact the global population, thus countermeasure platforms that enable rapid development of therapeutics against variants of SARS-CoV-2 are essential. We report use of a phage display human antibody library approach to rapidly identify neutralizing antibodies (nAbs) against SARS-CoV-2. We demonstrate the binding and neutralization capability of two nAbs, STI-2020 and STI-5041, against the SARS-CoV-2 WA-1 strain as well as the Alpha and Beta variants. STI-2020 and STI-5041 were protective when administered intravenously or intranasally in the golden (Syrian) hamster model of COVID-19 challenged with the WA-1 strain or Beta variant. The ability to administer nAbs intravenously and intranasally may have important therapeutic implications and Phase 1 healthy subjects clinical trials are ongoing.